IGC PHARMA INC (IGC)
US45408X3089 - Common Stock
Overall IGC gets a fundamental rating of 1 out of 10. We evaluated IGC against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IGC have multiple concerns. IGC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year IGC has reported negative net income.
IGC had a negative operating cash flow in the past year.
IGC had negative earnings in each of the past 5 years.
IGC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -125.56%, IGC is not doing good in the industry: 82.81% of the companies in the same industry are doing better.
With a Return On Equity value of -168.81%, IGC is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.56% | ||
| ROE | -168.81% | ||
| ROIC | N/A |
ROA(3y)-84.76%
ROA(5y)-60.82%
ROE(3y)-105.88%
ROE(5y)-74.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 60.04%, IGC is doing good in the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of IGC has grown nicely.
IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y64.59%
GM growth 5Y84.65%
2. Health
2.1 Basic Checks
IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IGC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IGC has more shares outstanding
IGC has a worse debt/assets ratio than last year.
2.2 Solvency
IGC has an Altman-Z score of -11.74. This is a bad value and indicates that IGC is not financially healthy and even has some risk of bankruptcy.
IGC's Altman-Z score of -11.74 is on the low side compared to the rest of the industry. IGC is outperformed by 77.08% of its industry peers.
IGC has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
IGC has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.74 |
ROIC/WACCN/A
WACC9.3%
2.3 Liquidity
A Current Ratio of 1.77 indicates that IGC should not have too much problems paying its short term obligations.
IGC has a Current ratio of 1.77. This is in the lower half of the industry: IGC underperforms 63.54% of its industry peers.
A Quick Ratio of 1.16 indicates that IGC should not have too much problems paying its short term obligations.
IGC's Quick ratio of 1.16 is on the low side compared to the rest of the industry. IGC is outperformed by 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The earnings per share for IGC have decreased by -2.51% in the last year.
IGC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.79%.
The Revenue for IGC have been decreasing by -23.46% on average. This is quite bad
EPS 1Y (TTM)-2.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
Revenue 1Y (TTM)-15.79%
Revenue growth 3Y14.33%
Revenue growth 5Y-23.46%
Sales Q2Q%-51.43%
3.2 Future
The Earnings Per Share is expected to grow by 16.99% on average over the next years. This is quite good.
IGC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.48% yearly.
EPS Next Y50.52%
EPS Next 2Y23.61%
EPS Next 3Y16.99%
EPS Next 5YN/A
Revenue Next Year-9%
Revenue Next 2Y1.66%
Revenue Next 3Y6.48%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IGC's earnings are expected to grow with 16.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.61%
EPS Next 3Y16.99%
5. Dividend
5.1 Amount
IGC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IGC PHARMA INC
NYSEARCA:IGC (11/25/2024, 8:04:00 PM)
After market: 0.4024 +0.03 (+7.31%)0.375
+0.02 (+5.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap29.04M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.56% | ||
| ROE | -168.81% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-2.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y50.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.79%
Revenue growth 3Y14.33%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y